Borosil Scientific Ltd

Borosil Scientific maintains a strong liquidity position, with a current ratio of 3.56, indicating the company can cover its short-term obligations more than three times over. The company's liquidity_fpt score is high, supported by positive operating cash flow of INR 1.2 billion and free cash flow of INR 310.3 million, which provides flexibility for reinvestment or debt servicing. Profitability metrics show a return on equity (ROE) of 6.63% and return on assets (ROA) of 5.27%, both below the industry median for Life Sciences Tools & Services. However, the company's operating margin of 7.8% (calculated from operating income of INR 343.1 million on revenue of INR 4.38 billion) is in line with the sector average, suggesting efficient cost management. The company's revenue is concentrated in two primary segments: Scientific - Laboratory Glass & Equipment and Process Systems. The Scientific segment accounts for the majority of revenue, with a strong presence in India and growing international demand for its pharmaceutical packaging solutions. The geographic exposure is primarily domestic, with limited international revenue disclosed in the latest financials. Looking ahead, Borosil Scientific is projected to grow revenue by 12% in the current fiscal year and 8% in the next, driven by increased demand for lab equipment and expansion in pharmaceutical packaging. This growth is supported by a capital expenditure of INR 141.6 million, primarily for capacity expansion and automation. The company faces moderate risk from liquidity constraints, as net cash is negative after subtracting total debt. However, the dilution risk is low, with no significant share issuance or ATM programs disclosed in the latest filings. The risk assessment composite score is medium, with the primary risk factor being the potential for margin compression due to competitive pricing in the lab glassware market. Recent events include the filing of a 10-K that highlights the company's expansion into the U.S. market through its pharmaceutical packaging solutions. The company also announced a new product line for life sciences applications, which is expected to drive revenue in the next fiscal year.